Full Text Journal Articles from
Abstract 29755773

Advertisement

Find full text journal articles








Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy.

PMID: 29755773 (view PubMed database entry)
DOI: 10.21037/jgo.2018.01.02 (read at publisher's website )
PMCID: PMC5934154 (free full text version available)

Download PDF Download PDF

Whitney L Guerrero, Gitonga Munene, Paxton V Dickson, Dina Darby, Andrew M Davidoff, Michael G Martin, Evan S Glazer, David Shibata, Jeremiah L Deneve,

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program.An IRB approved retrospective review was performed for the first 50 patients treated with CRS/HIPEC with clinicopathologic data described.Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11-73 years). Primary pathology included: appendix (40%, n=20), ovary (20%, n=10), colon (14%, n=7), desmoplastic small round cell tumor (14%, n=7) or other (12%, n=6). The median peritoneal cancer index (PCI) score was 15.5 (range, 1-39) and 92% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 9.0 days (range, 6-35 days). Eight patients (16%) suffered major morbidity with 2 (4%) 30-day mortalities.Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.

J Gastrointest Oncol (Journal of gastrointestinal oncology)
[2018, 9(2):338-347]

Cited: 0 times

AltMetric Statistics

Additional resources:




Advertisement

Disclaimer
0.4186 s